Galapagos NV, of Mechelen, Belgium, said it regained rights to GLPG1690, a selective autotaxin inhibitor, after the company mutually agreed to terminate inflammation alliance and option agreements with partner Janssen Pharmaceutica NV, of Beerse, Belgium, a unit of Johnson & Johnson.